Literature DB >> 8398139

A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms.

T W Lovenberg1, B M Baron, L de Lecea, J D Miller, R A Prosser, M A Rea, P E Foye, M Racke, A L Slone, B W Siegel.   

Abstract

We report the cloning and characterization of a novel serotonin receptor, designated as 5-HT7, which is coupled to the stimulation of adenylyl cyclase. 5-HT7 mRNA is expressed discretely throughout the CNS, predominantly in the thalamus and hypothalamus. 5-HT7 has a unique pharmacological profile that redefines agonist and antagonist classification of ligands previously thought to be "selective." The circadian phase of spontaneous neuronal activity of the rat suprachiasmatic nucleus of the hypothalamus advances in response to serotonin ligands with a pharmacological profile consistent exclusively with that of 5-HT7. These findings suggest a physiological role in the regulation of circadian rhythms for one subtype of serotonin receptor, 5-HT7, and provide a pharmacological test to evaluate its role in other neuronal systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398139     DOI: 10.1016/0896-6273(93)90149-l

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  123 in total

1.  [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors.

Authors:  D R Thomas; P J Atkinson; M Ho; S M Bromidge; P J Lovell; A J Villani; J J Hagan; D N Middlemiss; G W Price
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus.

Authors:  J C Ehlen; G H Grossman; J D Glass
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors.

Authors:  R E Wilcox; J E Ragan; R S Pearlman; M Y Brusniak; R M Eglen; D W Bonhaus; T E Tenner; J D Miller
Journal:  J Comput Aided Mol Des       Date:  2001-10       Impact factor: 3.686

Review 4.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

5.  Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines.

Authors:  Cécile Mahé; Michel Bernhard; Ionel Bobirnac; Corinna Keser; Erika Loetscher; Dominik Feuerbach; Kumlesh K Dev; Philippe Schoeffter
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

6.  Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 7.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

8.  Inhibition by 5-HT7 receptor stimulation of GABAA receptor-activated current in cultured rat suprachiasmatic neurones.

Authors:  F Kawahara; H Saito; H Katsuki
Journal:  J Physiol       Date:  1994-07-01       Impact factor: 5.182

Review 9.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

10.  Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.

Authors:  J C Gillin; W Jernajczyk; D C Valladares-Neto; S Golshan; M Lardon; S M Stahl
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.